Tharimmune Showcases Innovative Solutions at Key Conferences

Tharimmune to Highlight TH104 at Upcoming Fall Conferences

Tharimmune, Inc. (Nasdaq: THAR), a pioneering biotechnology firm located in Red Bank, NJ, is committed to developing groundbreaking therapies for severe medical needs including inflammation and immunology. The company has recently announced its participation in a series of prominent fall conferences that will showcase its lead asset, TH104. This innovative formulation is designed to combat the effects of powerful opioids, particularly in situations where individuals may be exposed to dangerous substances like fentanyl.

Key Conference Details

The Tharimmune team will reveal exciting new findings at several important medical gatherings. First up, the American College of Gastroenterology (ACG) Annual Scientific Meeting is scheduled for October 24-29, 2025, at the Phoenix Convention Center. At this event, the team plans to discuss critical advancements surrounding TH104.

ACG Annual Meeting Schedule

During the ACG event, Tharimmune will present its research on Sunday, October 26, 2025, from 3:30 p.m. to 4:30 p.m. Pacific Time, located in the Exhibit Hall of the Phoenix Convention Center. This session aims to enlighten participants on the challenges posed by ultra-potent opioids and how TH104 can play a vital role in managing these issues.

Further Presentations Planned

The company has also secured its presence at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place from November 7 to 10, 2025, in Washington, DC. At this conference, representatives from Tharimmune will delve deeper into TH104's potential applications beyond its primary focus.

The Liver Meeting® Agenda

Tharimmune will take the stage on Monday, November 10, 2025, at 1:00 p.m. Eastern Time, in the Washington Convention Center's Exhibit Hall. The audience will have the opportunity to hear insights regarding ongoing research and patient-centered approaches that may redefine treatment protocols in liver disease.

AAPS PharmSci 360: Innovation in Focus

Additionally, Tharimmune will be present at the AAPS PharmSci 360 event, scheduled from November 9 to 12, 2025, in San Antonio, TX. This conference is pivotal for pharmaceutical scientists and aims to address both fundamental and emerging scientific challenges.

Poster Presentation Highlights

At the AAPS event, Tharimmune will take part in a Late Breaker Poster Session. This session will be a key platform for the company to share late-breaking findings that may impact the development of new therapies and drugs, emphasizing the importance of its innovative TH104 formulation.

About Tharimmune, Inc.

Tharimmune is on the cutting edge, developing a strategic array of therapeutic candidates for critical medical needs. Leading the charge is TH104, which targets respiratory and central nervous system challenges associated with extreme opioid exposure. This formulation is intended particularly for military personnel and first responders who might face hazardous environments contaminated by high-potency opioids.

Tharimmune’s research extends beyond TH104, with initiatives aimed at addressing chronic conditions like pruritus in primary biliary cholangitis. With the introduction of TH023, the company is also venturing into treatment opportunities for autoimmune diseases. Furthermore, its innovative EpiClick™ Technology is paving the way for novel biologic treatments targeting specific tumor epitopes, aiming to provide patient specific solutions.

The firm is dedicated not just to advancement in research but also to ensuring long-term value for investors. As part of its commitment to innovation, Tharimmune has secured a licensing agreement with OmniAb, Inc., enabling access to their state-of-the-art antibody discovery technology, which enhances its capabilities in creating targeted therapeutic solutions.

Frequently Asked Questions

What is Tharimmune focused on at the upcoming conferences?

Tharimmune is showcasing its lead asset TH104, focusing on addressing severe opioid exposure in various medical situations.

When is Tharimmune presenting at the ACG Annual Scientific Meeting?

Tharimmune’s presentation at the ACG Annual Scientific Meeting is scheduled for October 26, 2025, from 3:30 p.m. to 4:30 p.m. Pacific Time.

What other conferences will Tharimmune be attending?

In addition to the ACG meeting, Tharimmune will attend The Liver Meeting® 2025 and AAPS PharmSci 360.

What are the potential applications of TH104?

TH104 is being developed for several indications, including respiratory and nervous system depression due to opioid exposure, as well as chronic pruritus.

How is Tharimmune ensuring long-term value for investors?

Tharimmune is committed to innovation and development, alongside strategic partnerships that enhance its research capabilities and market potential.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.